The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Therapeutic and prognostic impact of genetic alterations identified in nationwide genome screening for squamous cell lung cancer (LC-SCRUM-Japan).
 
Tomohiro Sakamoto
No Relationships to Disclose
 
Shingo Matsumoto
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Riken Genesis (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Eri Sugiyama
No Relationships to Disclose
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly Japan
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Nobuaki Kobayashi
No Relationships to Disclose
 
Takuma Yokoyama
No Relationships to Disclose
 
Masato Shingoji
No Relationships to Disclose
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Quintiles; Roche; Sumitomo Dainippon; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
 
Hiromi Aono
No Relationships to Disclose
 
Satoshi Hara
No Relationships to Disclose
 
Shunichi Sugawara
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Akimasa Sekine
Research Funding - Boehringer Ingelheim
 
Koichi Goto
Honoraria - AbbVie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Life Technologies; Lilly; Merck Serono; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Quintiles; RIKEN GENESIS; Roche; SRL Diagnostics; Taiho Pharmaceutical
Consulting or Advisory Role - Otsuka
Research Funding - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; OxOnc; Pfizer; Riken Genesis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda